mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases), By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines), By mRNA Type (Nucleoside-Modified mRNA, Self-Amplifying mRNA, Unmodified mRNA), By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization), By Region & Competition, 2020-2030F
Market Overview
The Global mRNA Platform Market was valued at USD 7.30 billion in 2024 and is projected t%li%grow at a CAGR of 3.56% through 2030. The mRNA (messenger RNA) platform is an advanced biotechnological innovation that enables synthetic RNA molecules t%li%deliver genetic instructions t%li%cells, prompting the production of specific proteins. This approach has demonstrated significant success in vaccine development and is expanding int%li%treatments for a range of diseases. Notably, in September 2023, BioNTech SE partnered with CEPI t%li%accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform’s importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered t%li%prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due t%li%their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications.
Key Market Drivers
Technological Advancements
Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 t%li%accelerate drug development. Techniques like codon optimization are being refined t%li%maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has als%li%improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications.
Key Market Challenges
Vaccine Hesitancy and Misinformation
A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts t%li%achieve herd immunity and prolonging outbreaks of preventable diseases. Public mistrust als%li%complicates health campaigns during emergencies, such as pandemics, and may extend skepticism t%li%other public health measures. Low vaccine coverage due t%li%hesitancy not only affects individual health outcomes but als%li%increases pressure on healthcare systems and obstructs disease control efforts at a population level.
Key Market Trends
Increase in the Number of Virtual Trials
The rise of virtual trials is reshaping drug development strategies, including those related t%li%mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access t%li%more diverse participant populations. CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps t%li%monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions.
Key Market Players
In this report, the Global mRNA Platform Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.
Available Customizations:
Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
The Global mRNA Platform Market was valued at USD 7.30 billion in 2024 and is projected t%li%grow at a CAGR of 3.56% through 2030. The mRNA (messenger RNA) platform is an advanced biotechnological innovation that enables synthetic RNA molecules t%li%deliver genetic instructions t%li%cells, prompting the production of specific proteins. This approach has demonstrated significant success in vaccine development and is expanding int%li%treatments for a range of diseases. Notably, in September 2023, BioNTech SE partnered with CEPI t%li%accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform’s importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered t%li%prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due t%li%their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications.
Key Market Drivers
Technological Advancements
Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 t%li%accelerate drug development. Techniques like codon optimization are being refined t%li%maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has als%li%improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications.
Key Market Challenges
Vaccine Hesitancy and Misinformation
A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts t%li%achieve herd immunity and prolonging outbreaks of preventable diseases. Public mistrust als%li%complicates health campaigns during emergencies, such as pandemics, and may extend skepticism t%li%other public health measures. Low vaccine coverage due t%li%hesitancy not only affects individual health outcomes but als%li%increases pressure on healthcare systems and obstructs disease control efforts at a population level.
Key Market Trends
Increase in the Number of Virtual Trials
The rise of virtual trials is reshaping drug development strategies, including those related t%li%mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access t%li%more diverse participant populations. CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps t%li%monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions.
Key Market Players
- AstraZeneca PLC
- Asuragen, Inc.
- Catalent Pharma Solutions
- Arcturus Therapeutics, Inc.
- BioNTech AG
- CRISPR Therapeutics Inc.
- AKESOgen, Inc.
- baseclick GmbH
- Accent Therapeutics Inc.
- Accanis Biotech F&E GmbH & C%li%KG
In this report, the Global mRNA Platform Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
- mRNA Platform Market, By Indication:
- Autoimmune Diseases
- Cancer
- Personalized Treatment
- Single Cancer Focused
- Infectious Diseases
- Rare Diseases
- Respiratory Diseases
- mRNA Platform Market, By Usability:
- Prophylactic Vaccines
- Therapeutic Drugs
- Therapeutic Vaccines
- mRNA Platform Market, By mRNA Type:
- Nucleoside-Modified mRNA
- Self-Amplifying mRNA
- Unmodified mRNA
- mRNA Platform Market, By End-User:
- Hospitals & Clinics
- Pharmaceutical Companies
- Research Organization
- mRNA Platform Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.
Available Customizations:
Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%li%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MRNA PLATFORM MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. ASIA PACIFIC MRNA PLATFORM MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Usability
6.2.3. By mRNA Type
6.2.4. By End User
6.2.5. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China mRNA Platform Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.1.2.2. By Usability
6.3.1.2.3. By mRNA Type
6.3.1.2.4. By End User
6.3.2. India mRNA Platform Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.2.2.2. By Usability
6.3.2.2.3. By mRNA Type
6.3.2.2.4. By End User
6.3.3. Australia mRNA Platform Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
6.3.3.2.2. By Usability
6.3.3.2.3. By mRNA Type
6.3.3.2.4. By End User
6.3.4. Japan mRNA Platform Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Indication
6.3.4.2.2. By Usability
6.3.4.2.3. By mRNA Type
6.3.4.2.4. By End User
6.3.5. South Korea mRNA Platform Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Indication
6.3.5.2.2. By Usability
6.3.5.2.3. By mRNA Type
6.3.5.2.4. By End User
7. EUROPE MRNA PLATFORM MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Usability
7.2.3. By mRNA Type
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France mRNA Platform Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Usability
7.3.1.2.3. By mRNA Type
7.3.1.2.4. By End User
7.3.2. Germany mRNA Platform Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Usability
7.3.2.2.3. By mRNA Type
7.3.2.2.4. By End User
7.3.3. Spain mRNA Platform Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Usability
7.3.3.2.3. By mRNA Type
7.3.3.2.4. By End User
7.3.4. Italy mRNA Platform Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.4.2.2. By Usability
7.3.4.2.3. By mRNA Type
7.3.4.2.4. By End User
7.3.5. United Kingdom mRNA Platform Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
7.3.5.2.2. By Usability
7.3.5.2.3. By mRNA Type
7.3.5.2.4. By End User
8. NORTH AMERICA MRNA PLATFORM MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Usability
8.2.3. By mRNA Type
8.2.4. By End User
8.2.5. By Country
8.3. North America: Country Analysis
8.3.1. United States mRNA Platform Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Usability
8.3.1.2.3. By mRNA Type
8.3.1.2.4. By End User
8.3.2. Mexico mRNA Platform Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Usability
8.3.2.2.3. By mRNA Type
8.3.2.2.4. By End User
8.3.3. Canada mRNA Platform Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Usability
8.3.3.2.3. By mRNA Type
8.3.3.2.4. By End User
9. SOUTH AMERICA MRNA PLATFORM MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Usability
9.2.3. By mRNA Type
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil mRNA Platform Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Usability
9.3.1.2.3. By mRNA Type
9.3.1.2.4. By End User
9.3.2. Argentina mRNA Platform Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Usability
9.3.2.2.3. By mRNA Type
9.3.2.2.4. By End User
9.3.3. Colombia mRNA Platform Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Usability
9.3.3.2.3. By mRNA Type
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA MRNA PLATFORM MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Usability
10.2.3. By mRNA Type
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa mRNA Platform Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Usability
10.3.1.2.3. By mRNA Type
10.3.1.2.4. By End User
10.3.2. Saudi Arabia mRNA Platform Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Usability
10.3.2.2.3. By mRNA Type
10.3.2.2.4. By End User
10.3.3. UAE mRNA Platform Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Usability
10.3.3.2.3. By mRNA Type
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL MRNA PLATFORM MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE ANALYSIS
16. COMPETITIVE LANDSCAPE
16.1. Amgen Inc. AstraZeneca PLC
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Asuragen, Inc.
16.3. Catalent Pharma Solutions
16.4. Arcturus Therapeutics, Inc.
16.5. BioNTech AG
16.6. CRISPR Therapeutics Inc.
16.7. AKESOgen, Inc.
16.8. Baseclick GmbH
16.9. Accent Therapeutics Inc.
16.10.Accanis Biotech F&E GmbH & Co KG
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MRNA PLATFORM MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. ASIA PACIFIC MRNA PLATFORM MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Usability
6.2.3. By mRNA Type
6.2.4. By End User
6.2.5. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China mRNA Platform Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.1.2.2. By Usability
6.3.1.2.3. By mRNA Type
6.3.1.2.4. By End User
6.3.2. India mRNA Platform Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.2.2.2. By Usability
6.3.2.2.3. By mRNA Type
6.3.2.2.4. By End User
6.3.3. Australia mRNA Platform Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
6.3.3.2.2. By Usability
6.3.3.2.3. By mRNA Type
6.3.3.2.4. By End User
6.3.4. Japan mRNA Platform Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Indication
6.3.4.2.2. By Usability
6.3.4.2.3. By mRNA Type
6.3.4.2.4. By End User
6.3.5. South Korea mRNA Platform Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Indication
6.3.5.2.2. By Usability
6.3.5.2.3. By mRNA Type
6.3.5.2.4. By End User
7. EUROPE MRNA PLATFORM MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Usability
7.2.3. By mRNA Type
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France mRNA Platform Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Usability
7.3.1.2.3. By mRNA Type
7.3.1.2.4. By End User
7.3.2. Germany mRNA Platform Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Usability
7.3.2.2.3. By mRNA Type
7.3.2.2.4. By End User
7.3.3. Spain mRNA Platform Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Usability
7.3.3.2.3. By mRNA Type
7.3.3.2.4. By End User
7.3.4. Italy mRNA Platform Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.4.2.2. By Usability
7.3.4.2.3. By mRNA Type
7.3.4.2.4. By End User
7.3.5. United Kingdom mRNA Platform Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
7.3.5.2.2. By Usability
7.3.5.2.3. By mRNA Type
7.3.5.2.4. By End User
8. NORTH AMERICA MRNA PLATFORM MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Usability
8.2.3. By mRNA Type
8.2.4. By End User
8.2.5. By Country
8.3. North America: Country Analysis
8.3.1. United States mRNA Platform Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Usability
8.3.1.2.3. By mRNA Type
8.3.1.2.4. By End User
8.3.2. Mexico mRNA Platform Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Usability
8.3.2.2.3. By mRNA Type
8.3.2.2.4. By End User
8.3.3. Canada mRNA Platform Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Usability
8.3.3.2.3. By mRNA Type
8.3.3.2.4. By End User
9. SOUTH AMERICA MRNA PLATFORM MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Usability
9.2.3. By mRNA Type
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil mRNA Platform Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Usability
9.3.1.2.3. By mRNA Type
9.3.1.2.4. By End User
9.3.2. Argentina mRNA Platform Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Usability
9.3.2.2.3. By mRNA Type
9.3.2.2.4. By End User
9.3.3. Colombia mRNA Platform Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Usability
9.3.3.2.3. By mRNA Type
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA MRNA PLATFORM MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Usability
10.2.3. By mRNA Type
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa mRNA Platform Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Usability
10.3.1.2.3. By mRNA Type
10.3.1.2.4. By End User
10.3.2. Saudi Arabia mRNA Platform Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Usability
10.3.2.2.3. By mRNA Type
10.3.2.2.4. By End User
10.3.3. UAE mRNA Platform Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Usability
10.3.3.2.3. By mRNA Type
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL MRNA PLATFORM MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE ANALYSIS
16. COMPETITIVE LANDSCAPE
16.1. Amgen Inc. AstraZeneca PLC
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Asuragen, Inc.
16.3. Catalent Pharma Solutions
16.4. Arcturus Therapeutics, Inc.
16.5. BioNTech AG
16.6. CRISPR Therapeutics Inc.
16.7. AKESOgen, Inc.
16.8. Baseclick GmbH
16.9. Accent Therapeutics Inc.
16.10.Accanis Biotech F&E GmbH & Co KG
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
